ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.72
0.56%
US Tech 100
17,640.80
0.00%
S&P 500
5,214.08
0.51%
US Dollar vs CAD
1.3683
0.04%
Bitcoin
63,222.00
0.28%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Janux Therapeutics Inc (JANX)

  7. Janux Therapeutics Inc (JANX) News

JANX

Janux Therapeutics (JANX)

Janux Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:JANX
DateTimeSourceHeadlineSymbolCompany
05/08/20248:13AMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:JANXJanux Therapeutics Inc
05/07/20243:01PMBusiness WireJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
03/08/20243:47PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
03/08/20243:23PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
03/08/20243:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
03/08/20243:01PMBusiness WireJanux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
02/29/20244:30PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
02/29/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
02/29/202412:22AMBusiness WireJanux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
02/28/20248:55PMEdgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:JANXJanux Therapeutics Inc
02/28/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
02/27/20248:50PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
02/27/20244:23PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
02/27/20244:00PMBusiness WireJanux Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:JANXJanux Therapeutics Inc
02/26/20243:05PMBusiness WireJanux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid TumorsNASDAQ:JANXJanux Therapeutics Inc
02/20/20247:00AMBusiness WireJanux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008NASDAQ:JANXJanux Therapeutics Inc
02/09/20243:31PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
02/01/20243:15PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:JANXJanux Therapeutics Inc
01/08/20248:00AMBusiness WireJanux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific OfficerNASDAQ:JANXJanux Therapeutics Inc
01/03/20243:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
01/03/20243:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
01/03/20243:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
01/03/20243:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
01/03/20243:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
01/03/20243:45PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
11/07/20233:19PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:JANXJanux Therapeutics Inc
11/07/20233:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
11/07/20233:01PMBusiness WireJanux Therapeutics Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
09/07/20235:14PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
08/14/20233:33PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JANX

Your Recent History

USOTC
TXTM
ProText Mobility (PK)
USOTC
EMGE
Emergent Health (PK)
USOTC
SONG
Music Licensing (PK)
USOTC
SHMP
NaturalShrimp (QB)
USOTC
RDAR
Raadr (PK)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
YCRM
Yuenglings Ice Cream (PK)
USOTC
CLNV
Clean Vision (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
GSTC
Globestar Therapeutics (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
IPIX
Innovation Pharmaceuticals (CE)
USOTC
ERHE
ERHC Energy (CE)
USOTC
BABL
Buildablock (PK)
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved